Thank you for submitting your research manuscript for consideration to The EMBO Journal editorial office. I have now had the opportunity to read the manuscript carefully, check the related literature and discuss it with the other members of our editorial team. I am sorry to say that the outcome of this assessment was not a positive one, as we all had to conclude that we are unable to offer publication.
We certainly appreciate the identification of detailed characterization of a sub-picomolar campresponse to relaxin. We also understand that a significant amount of cellular assays determines the signalosome components involved. Irrespective of this potentially important finding that might indeed explain some of the reported biological relaxin functions, we still had to realize that the description of the signaling events remains, at least at this stage, detached from any physiological output. Therefore, and at least from our rather more general and highly competitive journal, we all had to conclude that the data do currently not amount to the significant advance and insight that we have to demand according to the aim and scope of our general journal, compared to the more specialized literature. Therefore, and also to avoid unnecessary delays for you and your work, we decided to return the manuscript with the message that we are unable to offer further proceedings.
Please let me add that we are looking for complete papers that describe original research of general rather than specialist interest in molecular biology and we can only afford to select those manuscripts that merit urgent publication because they report novel findings of wide biological significance, sufficient level of molecular understanding and physiological relevance. This is in fact a very tall order and it means that we end up rejecting by far the majority of the very many manuscripts we receive every day at our editorial office. I am sorry to have to disappoint you on this occasion, but I hope that you nevertheless might consider our journal for publication of your future studies.
Yours sincerely, Editor The EMBO Journal ** As a service to authors, Nature Publishing Group provides authors with the ability to transfer a manuscript that one journal cannot offer to publish to another journal, without the author having to upload the manuscript data again. To transfer your manuscript to another NPG journal using this service, please click on <http://mts-emboj.nature.com/cgibin/main.plex?el=A1z6JXM7A7OOh2X2A9rDAvtgHlONdnBnTlsTNYRQZ>
Rebuttal 26 January 2010
Thank you for considering our manuscript for EMBO J. We were a little surprised that you were not inclined to put it out for review since we were genuinely excited by its novelty -and aware of its uniqueness in the GPCR-signalling world at the moment. However we must accept the responsibility for being too close to the subject and not seeing that we really needed to stress the importance of this study for readers less close to the area.
There are various reports of 'signalosomes' around the literature -one in the current EMBO J for instance -however these have served to be incremental, although elegant, nuances on pathways that have already been established by other means. What we have found here for relaxin is a completely new pathway -completely overlooked -and missed -by traditional analyses. The conceptual breakthrough is that the whole system is already in place even in the absence of hormone -only the receptor is required to assemble the complex. What has made the discovery of this complex possible is the application of new single cell methods. This has allowed detection of responses to attomolar responses; the only instances of responses in this concentration range in the literature are to cytokines or neurosteroids -none to GPCRs. Every molecule participating in the complex has been identified here -in this first study. And, we are left with a potential explanation for the physiological effects of circulating relaxin. The physiological relevance is that a mystery is potentially solved; the implications for a general audience is that such complexes may be far more widespread and should be searched for -by the means we have adopted -in attempting to understand the actions of other hormones and neurotransmitters. To stress the physiological relevance, in many tissues throughout the body, including the human heart, relaxin exerts important physiological effects. However, the heart does not produce relaxin, and thus any physiological effects observed in the heart must be due to circulating relaxin. However, until now, no cellular responses have been observed to the low concentrations of relaxin in the circulation.
What we present here is a mechanism, whereby low concentrations of relaxin in the circulation, can exert their physiological effects. Not only do we describe this mechanism in model cells, but we show that the effect occurs in primary rat cardiac fibroblasts, a target that endogenously expresses the GPCR. We should certainly stress and re-word the paper along these lines, so that readers can see this study as a critical breakthrough that offers an exemplary mechanism for addressing what might appear to be highly challenging aspects of signaling. Cast in that light I think the manuscript might much more clearly appear well-suited to the high standards of important breakthrough papers published in EMBO J. I would like the opportunity to go back through the paper to make these points more directly so that you could determine whether you and colleagues might agree that it could be deserving of a rigourous review.
With many thanks for your attention
Sincerely yours
Dermot Cooper 2nd Editorial Decision 29 January 2010
I just heard back from one of our external advisors. Based on this input I will expose your paper to in-depth peer review.
I will certainly get back to you as soon as I have received comments from our referees.
Yours sincerely,
Editor
The EMBO Journal
3rd Editorial Decision 22 February 2010
Thank you very much for submitting your manuscript to The EMBO Journal. I did receive assessments from three independent scientists that you find enclosed below. Your paper that reports on relaxin signaling via a pre-assembled protein complex raised certainly some interest. However, the reports are also very clear in concluding that the experimental support for this proposal remains too limited, at least considering the perspective and aim of our very general and highly competitive journal. Specifically, ref#1 is as yet not convinced by the sole pharmacological perturbations and the limited functional read-out. Rather similarly, ref#2 requests significant additional data to substantiate this signaling paradigm and provides ample suggestions how this should be done. Lastly, ref#3 asks for experiments that should corroborate pre-assembled complex formation and at least some functional significance. As these reports indicate significant additional experimental work with a currently rather uncertain outcome, I hope you understand that we are at this stage unable to invite a timely very restricted round of single revisions as this would essentially mean that we already commit to the paper. With this explicit policy of our journal and in light of the current limitations of your study, I am sorry that I have formerly no other choice than to reject the current paper.
However, and clearly appreciating the potential of the study, and on condition that you would be able to provide the requested experimental and functional support for the proposed signaling scheme, we would be happy to reassess your findings in the future. In case you might consider such an option, I have to stress that a new manuscript will NOT be treated as a revision, but would be assessed as NEW SUBMISSION and would therefore be evaluated afresh, also with respect to the literature and the novelty of your findings at the time of submission and without any obligation to send the paper out for peer-review or to involve the current set of referees.
I am really sorry that we are unable to reach a more positive conclusion at this stage, but I still hope that the comments of our referees help to significantly improve the current dataset to enable timely publication.
Editor
The EMBO Journal REFEREE REPORTS:
Referee #1 (Remarks to the Author):
This paper is an extensive and well controlled study of signaling through the G protein-coupled relaxin receptor 1, RXFP1, using a Epac-FRET reporter to assess cAMP levels. The finding that RXFP1 responds to sub-picomolar concentrations of relaxin by increasing cAMP significantly, and the observation that the AC2 couples to RXFP1 via AKAP79 are novel. However, the mode of signaling by relaxin through RXFP1 is largely similar to what is earlier reported over the whole concentration range and the role of AKAP79 is similar in positioning of the AC versus other GPCRs. Furthermore, the majority of the experiments are pharmacological experiments and perturbations looking at cAMP as the only readout. This suggests that the paper, although solid and well performed, may be better suited for a more specialized journal.
Specific comments: Does the biphasic response resulting in low and high cAMP responses to sub-picomolar and nanomolar concerntyrations of relaxin correspond to the high and low affinity binding sites for relaxin on RXFP1?
The molecular interaction experiment in Fig 6 is the weakest part. The results from the GST pull down assays should be corroborated by data other interaction assays. Furthermore, the experiment shown does not appear to correlate well with the amalgamated data from several pull down experiments. For example, there is quite a lot of AKAP79 pulled down in the GST control on the blot, but not in the quantification. Also for PDE4D3 and PKA cat the blot does not appear to be very representative versus the quantified data.
Referee #2 (Remarks to the Author):
This is a very novel and provocative study that presents an entirely new paradigm for cAMP signalling. There is extensive data presented in this study and, no doubt, it will stimulate much interest and further research not least to see whether this type of complex represents an isolated instance or not. The points below are intended as pointers to strengthen this interesting study.
1. Is there evidence from receptor binding studies of a component binding at the extremely high affinities implied from functional studies? What fraction of receptors has such affinity? Are the molar amounts of receptor and adenylyl cyclase at sensible enough numbers to envisage these couplings?
2. To what extent are these phenomena reversible? If binding occurs at such high affinity then how easily is it reversed? How easily is the functional output reversed by removal of relaxin, washing and re-addition? Is this high affinity component desensitized easily? 3. One issue that needs some thought and clarification relates to the way in which the authors assess changes in cAMP. They use area under the cure (AUC) a 5 min and it is not very clear why this is done, especially as this is really quite an unusual way to measure cAMP and the authors identify quite an unusual response. They should clarify why they don't use the method that is routinely used by others in the filed, namely to simply use fluorescence ratio change at peak response. Indeed, given their unusual data it would be very useful for them to additionally analyze their data in this way and present it, especially as regards this initial response due to high affinity receptors.
4. Moreover, simply choosing a 5 min sampling time seems to be rather arbitrary and requires justification and some additional experimentation / data analysis at other time points again, especially as relating to the response due to high affinity receptors. From the curves shown it looks like, at least in some cases, at 5 min the response is not at a plateau.
5. The authors need to provide information relating to probe saturation. Indeed, it is difficult to judge if certain of the experiments whether there is significant difference simply because the probe is saturated in the different conditions that are compared (e.g. Fig 3D, RLX 10nM ). This needs further experimentation to resolve. 7. p14. The authors state that 'but only one isoform, PDE4D3, had a similar pull-down profile to that of -arrestin 2? What does this statement mean? Confusing? One presumes that the PDE4D isoforms that was pull-down migrated with the size expected of PDE4D3, rather than PDE4D5? (i) If this is true please clarify the statement and give the observed MWts and a reference that reports these based upon studies with recombinant enzymes.
(ii) Is only PDE4 pull-down in this systems? This would be difficult using blotting as antisera, but simply by performing PDE assays {plus minus} 10 micromolar rolipram would indicate whether this activity was entirely, predominantly or somewhat PDE4.
8. Title and p14. The authors make the unequivocal statement that beta-arrestin sequestered PDE4D3 is in a complex with RXFP1, AKAP-79 and AC2. However, such a definite statement requires some contextual explanation, some caveats to be explained and some additional experimentation.
(i) It seems that identification of PDE4D3 came from pull-down studies using GST fusion proteins of fragments of the C-terminal tail of RXFP1. This has not been confirmed by pull-downs using the intact receptor in mammalian cells or any of its co-interacting species, particularly AC2, (ii) Importantly, the authors need to spend time in the discussion to put these data in context with the well-established preference of beta-arrestin2 for sequestering PDE4D5 over PDE4D3, due to the additional binding site for beta-arrestin found in the isoforms-specific N-terminal region of PDE4D5 (Bolger, G.B., et al. (2003) 27, when recruited to the beta2-adrenoceptor in a complex with AKAP79, which the authors implicate as existing in their complex as well. Notwithstanding this, it is clear that betaarrestin2 can also sequester PDE4D3 as it has the single 'common' binding site for it on the catalytic unit. If, as suggested, a beta-arrestin2-PDE4D3 complex is selectively sequestered to the RXFP1:AKAP79:AC2 complex then it suggests that one of these proteins may, additional, bind PDE4D3 through its unique N-terminal region. This is unlikely to be AKAP79 as it is found in the PDE4D5/beta-arrestin/Beta2-AR/AKAP79 complex, making it likely that either RXFP1 or AC2 bind PDE4D3. This needs discussion, as it clearly is an important and novel finding that needs to be set out and clarified in light of current knowledge as by ignoring this important issue it confuses rather than aids understanding. Indeed, the authors may have here identified a new regulatory system where different PDE4 species sequestered to beta-arrestin can be selectively recruited to interactions not only of the receptors with beta-arrestins but also with components in the complex with certain beta-arrestin-sequestered PDE4 species. It would be useful if the authors could make some effort to determine if PDE4D3, rather than PDE4D5, might interact directly with either RXFP1 or AC2. There are publications showing that it is possible to express PDE4D3 as a fusion protein, which could then be probed directly with the various RXFP1 fragments, for example. Biol. Chem. 282, [34235] [34236] [34237] [34238] [34239] [34240] [34241] [34242] [34243] [34244] [34245] [34246] [34247] [34248] [34249] . Is this true in this system? 9. The authors make statements concerning PDE4D3 in cardiac fibroblasts. However, they are using a pan-PDE4D antiserum and inferring PDE4D3 from molecular size. However, PDE4D8, PDE4D9 and PDE4D11 all run at exactly the same place on SDS-PAGE and cannot be identified. Thus the authors should be careful to claim PDE4D3 identity in these cells without more experimentation.
RT-PCR could be used to identify which of these species have transcripts in these cells. Also I note that a PDE4D3 specific antiserum is on sale from Everest Biotech (http://www.everestbiotech.com/acatalog/EB07542.html#aEB07542) which would greatly facilitate the authors studies and allow claims concerning this isoform being in the complex to be confirmed.
10. In presence of rolipram, then relaxin 10fM does not increase cAMP. If this concentration of RLX can generate cAMP in the presence of active PDE4, why should this increase not be visible when PDE4 is inhibited? (suppl Fig 2) ???
11. It is claimed that the physiological relevance of this response occurs at sub-picomolar concentrations. However, given that the low circulating levels of relaxin are in the 10pM range, this is within the concentration range that gives the second response in the biphasic curve. Does this mean that the complex they describe is basically responsible for the basal (constitutive) activity of the receptor in vivo?
Referee #3 (Remarks to the Author):
This manuscript describes experiments that make use of cAMP biosensors in HEK293 cells to assess the ability of relaxin to increase cAMP levels through the RXFP1 receptor. The authors define a previously-undescribed sub-picomolar response of RXFP1 that can be selectively disrupted by blocking AKAP interactions, knocking down beta-arrestin2, or inhibiting the activity of PDE4 or PKA. The authors also present data to support the idea that RXFP1 can be found in complex with AKAP-79, beta-arrestin2, PDE4D3 and AC2. The functional and pharmacological data shown in this manuscript are novel and interesting. However, the protein-protein interaction data, as presently shown, are not convincing. Moreover, no evidence is provided to link the protein-protein interaction data to the functional studies. Specific comments are as follows:
1. The protein-protein interaction data shown in Figure 6B -G are all from GST pull-down experiments using fragments of RXFP1. However, given that the title of the manuscript refers to a "pre-assembled RXFP1, beta-arrestin2, PDE4D3, AKAP-79, AC2 complex", the authors should confirm that these interactions actually occur in a cellular context. This could be done via coimmunoprecipitation and/or BRET/FRET approaches. The co-IP and/or BRET/FRET studies should be performed in both the absence and presence of relaxin stimulation in order to assess if the putative cellular complex is truly "pre-assembled", as the authors claim. Additionally, the authors' claim that mutation of Ser704 on RXFP1 disrupts interaction with beta-arrestin2 should be examined via co-IP and/or BRET/FRET rather than just inferred from functional experiments.
2. At present, there is one panel of co-immunoprecipitation data ( Fig. 6A ), which shows that both RXFP1 and AKAP-79 can be co-immunoprecipitated with AC2. However, in the authors' model ( Fig. 7) , AKAP-79 is the link between RXFP1 and AC2. Thus, the experiment that really should be done is to co-immunoprecipitate RXP1 with AC2 (as shown in panel 6A) and then assess whether or not this interaction is disrupted by siRNA knockdown of AKAP-79 (or by mutations to RXFP1 that disrupt the association of AKAP-79). In this way, it could be determined whether AKAP-79 is truly required for linking RXFP1 to AC2, which is the model that the authors propose.
3. The most glaring omission from this manuscript is the lack of data to link the formation of the putative physical complex of proteins to the observed sub-picomolar responses of RXFP1 to relaxin. The authors do a good job of showing that the sub-picomolar responses can be blocked by interfering with beta-arrestin2, AKAPs, and PDE isoforms, but where is the evidence that these proteins need to be in physical complex with RXFP1 in order to exert their effects on RXFP1 signaling? The most convincing way that this could be shown would be to create a mutant version of RXFP1 that lack association with some or all of the components of the putative complex, and then show that this mutant RXFP1 is deficient in its sub-picomolar responses to relaxin. For example, if a mutant RXFP1 could be created that did not associate with AKAP-79 (presumably a mutation somewhere between amino acids 673 and 703, the region of RXFP1 that binds to AKAP-79 as shown in Figure 6C ), then this mutant could be used to address the point raised above in point #2 (whether or not AKAP-79 is truly required for linking RXFP1 to AC2) and could also be used in functional studies to establish the importance of the putative cellular complex for RXFP1 signaling.
Resubmission 14 May 2010
Reviewers comments
Referee #1 (Remarks to the Author): This paper is an extensive and well controlled study of signaling through the G protein-coupled relaxin receptor 1, RXFP1, using a Epac-FRET reporter to assess cAMP levels. The finding that RXFP1 responds to sub-picomolar concentrations of relaxin by increasing cAMP significantly, and the observation that the AC2 couples to RXFP1 via AKAP79 are novel. However, the mode of signaling by relaxin through RXFP1 is largely similar to what is earlier reported over the whole concentration range and the role of AKAP79 is similar in positioning of the AC versus other GPCRs. Furthermore, the majority of the experiments are pharmacological experiments and perturbations looking at cAMP as the only readout. This suggests that the paper, although solid and well performed, may be better suited for a more specialized journal. The molecular interaction experiment in Fig 6 is the weakest part. The results from the GST pull down assays should be corroborated by data other interaction assays. Furthermore, the experiment shown does not appear to correlate well with the amalgamated data from several pull down experiments. For example, there is quite a lot of AKAP79 pulled down in the GST control on the blot, but not in the quantification. Also for PDE4D3 and PKA cat the blot does not appear to be very representative versus the quantified data.
The molecular interaction experiments have now been extensively strengthened -the original data described in the GST pull-down experiments has now been confirmed with two separate series of co-IP experiments: studies looking for proteins that co-IP with AC2-HA, and studies looking for proteins that co-IP with an over-expressed dominant negative PDE4D3 construct. This data confirms the original GST pull-down experiments, and shows molecular interactions between RXFP1, AKAP79 and AC2, and RXFP1, β-arrestin 2, PDE4D3 and PKA. Taking this one step further, we have also established the interaction points between these proteins, in both molecular (co-IP) and functional (cAMP) terms, such that AKAP79 interacts with helix 8 of RXFP1 to scaffold AC2 to the receptor, and β-arrestin 2 binds to Ser704 of the RXFP1 C-terminal tail, which allows the associated recruitment of PDE4D3 and PKA.
*********** Referee #2 (Remarks to the Author): This is a very novel and provocative study that presents an entirely new paradigm for cAMP signaling. There is extensive data presented in this study and, no doubt, it will stimulate much interest and further research not least to see whether this type of complex represents an isolated instance or not. The points below are intended as pointers to strengthen this interesting study. 4. Moreover, simply choosing a 5 min sampling time seems to be rather arbitrary and requires justification and some additional experimentation / data analysis at other time points again, especially as relating to the response due to high affinity receptors. From the curves shown it looks like, at least in some cases, at 5 min the response is not at a plateau.
This has now been clarified within the methods section of the paper. All initial experiments, including a number of the inhibitor studies were conducted over a 25 min period (with 20 min of relaxin stimulation, followed by addition of the FIP maximum response cocktail). There is no difference in the outcome if data is analyzed over this entire 20 min or in only the first 5 min (nor any arbitrary points in between). Once the response reaches plateau (which occurs by 5 min), there is no change in the magnitude of the cAMP response beyond this point. Thus subsequent experiments were performed over a 5 min time-course.
5. The authors need to provide information relating to probe saturation. Indeed, it is difficult to judge if certain of the experiments whether there is significant difference simply because the probe is saturated in the different conditions that are compared (e.g. Fig 3D, RLX 10nM ). This needs further experimentation to resolve. Fig 1B) (ii) Is only PDE4 pull-down in this system? This would be difficult using blotting as antisera, but simply by performing PDE assays {plus minus} 10 micromolar rolipram would indicate whether this activity was entirely, predominantly or somewhat PDE4. 8. Title and p14. The authors make the unequivocal statement that beta-arrestin sequestered PDE4D3 is in a complex with RXFP1, AKAP-79 and AC2. However, such a definite statement requires some contextual explanation, some caveats to be explained and some additional experimentation. (i) It seems that identification of PDE4D3 came from pull-down studies using GST fusion proteins of fragments of the C-terminal tail of RXFP1. This has not been confirmed by pulldowns using the intact receptor in mammalian cells or any of its co-interacting species, particularly AC2, (ii) Importantly, the authors need to spend time in the discussion to put these data in context with the wellestablished preference of beta-arrestin2 for sequestering PDE4D5 over PDE4D3, due to the additional binding site for beta-arrestin found in the isoforms-specific N-terminal region of PDE4D5 (Bolger, G.B., et al. 27, when recruited to the beta2-adrenoceptor in a complex with AKAP79, which the authors implicate as existing in their complex as well. Notwithstanding this, it is clear that beta-arrestin2 can also sequester PDE4D3 as it has the single 'common' binding site for it on the catalytic unit. If, as suggested, a beta-arrestin2-PDE4D3 complex is selectively sequestered to the RXFP1:AKAP79:AC2 complex then it suggests that one of these proteins may, additional, bind PDE4D3 through its unique N-terminal region. This is unlikely to be AKAP79 as it is found in the PDE4D5/betaarrestin/ Beta2-AR/AKAP79 complex, making it likely that either RXFP1 or AC2 bind PDE4D3. This needs discussion, as it clearly is an important and novel finding that needs to be set out and clarified in light of current knowledge as by ignoring this important issue it confuses rather than aids understanding. Indeed, the authors may have here identified a new regulatory system where different PDE4 species sequestered to beta-arrestin can be selectively recruited to interactions not only of the receptors with beta-arrestins but also with components in the complex with certain beta-arrestin-sequestered PDE4 species. It would be useful if the authors could make some effort to determine if PDE4D3, rather than PDE4D5, might interact directly with either RXFP1 or AC2. There are publications showing that it is possible to express PDE4D3 as a fusion protein, which could then be probed directly with the various RXFP1 fragments, for example.
This has now been clarified within the results section of the paper, and within the first figure legend. Even upon application of a maximal concentration of relaxin (100 nM;
This has now been addressed within the discussion. 9. The authors make statements concerning PDE4D3 in cardiac fibroblasts. However, they are using a pan-PDE4D antiserum and inferring PDE4D3 from molecular size. However, PDE4D8, PDE4D9 and PDE4D11 all run at exactly the same place on SDS-PAGE and cannot be identified. Thus the authors should be careful to claim PDE4D3 identity in these cells without more experimentation.
Although we have identified a response to sub-picomolar concentrations of relaxin in cardiac fibroblasts, we have not assessed the effect of inhibition of components of the RXFP1-signalosome within these cells. We have now performed thorough experimentation in HEK293 cells to confirm the specific involvement of PDE4D3 within the RXFP1-signalosome (see response above).
10. In presence of rolipram, then relaxin 10fM does not increase cAMP. If this concentration of RLX can generate cAMP in the presence of active PDE4, why should this increase not be visible when PDE4 is inhibited? (suppl Fig 2) ??? et al, 2006; Efendiev et al, 2010; Willoughby et al, 2010) .
This point has been clarified within the discussion. We suggest that AKAP79 is also exerting a tonic inhibition upon AC2, such that no further cAMP can be produced than what is evident upon stimulation of RXFP1 with sub-picomolar concentrations of relaxin, or indeed the levels induced by inhibition of PDE4 under basal conditions. Interestingly, a recent paper (Efendiev et al, 2010) has also reported an inhibitory effect of AKAP79 upon AC2, as is the case for a number of AC isoforms, including AC2, AC5, AC6 and AC8 (Bauman
The 10 pM range is the highest level of relaxin that has been measured in the circulation. These measurements are also limited by the sensitivity of these ELIZA assays -thus it is likely that relaxin is also regularly present at much lower concentrations. The lower range mentioned within the manuscript (8pM) would not cause a notable stimulation of the classical response (perhaps a 2% increase in cAMP above the 'basal' levels measured using traditional cAMP assays within the classical concentration range). So this sub-picomolar relaxin response does have a greater functional relevance for circulating concentrations of relaxin over the classical concentration range, and coupled with a constitutive activity of the receptor in vivo, this protein complex is highly physiologically significant.
Referee #3 (Remarks to the Author): This manuscript describes experiments that make use of cAMP biosensors in HEK293 cells to assess the ability of relaxin to increase cAMP levels through the RXFP1 receptor. The authors define a previously-undescribed subpicomolar response of RXFP1 that can be selectively disrupted by blocking AKAP interactions, knocking down betaarrestin2, or inhibiting the activity of PDE4 or PKA. The authors also present data to support the idea that RXFP1 can be found in complex with AKAP-79, beta-arrestin2, PDE4D3 and AC2. The functional and pharmacological data shown in this manuscript are novel and interesting. However, the proteinprotein interaction data, as presently shown, are not convincing. Moreover, no evidence is provided to link the protein-protein interaction data to the functional studies. Specific comments are as follows:
We have now drastically improved the protein-protein interaction data within the manuscript. The original GST pulldown studies have been supported by two extensive co-IP studies using the fulllength receptor in intact cells: all proteins within the RXFP1-signalosome initially identified by the GST pull-down assay have also been found to co-IP with both AC2-HA and PDE4D3. Furthermore, the proof for these protein-protein interactions has been strengthened by studies assessing the effect of targeted knockdown of specific proteins within the complex: AKAP79 or β-arrestin 2. Based upon our original model, these knockdowns had the anticipated effects in both molecular and functional experiments. Thus we have strengthened the links between the protein-protein interaction data and the functional studies.
We 2. At present, there is one panel of co-immunoprecipitation data (Fig. 6A) , which shows that both RXFP1 and AKAP-79 can be co-immunoprecipitated with AC2. However, in the authors' model (Fig. 7) , AKAP-79 is the link between RXFP1 and AC2. Thus, the experiment that really should be done is to co-immunoprecipitate RXP1 with AC2 (as shown in panel 6A) and then assess whether or not this interaction is disrupted by siRNA knockdown of AKAP-79 (or by mutations to RXFP1 that disrupt the association of AKAP-79). In this way, it could be determined whether AKAP-79 is truly required for linking RXFP1 to AC2, which is the model that the authors propose. 3. The most glaring omission from this manuscript is the lack of data to link the formation of the putative physical complex of proteins to the observed sub-picomolar responses of RXFP1 to relaxin. The authors do a good job of showing that the sub-picomolar responses can be blocked by interfering with beta-arrestin2, AKAPs, and PDE isoforms, but where is the evidence that these proteins need to be in physical complex with RXFP1 in order to exert their effects on RXFP1 signaling? The most convincing way that this could be shown would be to create a mutant version of RXFP1 that lack association with some or all of the components of the putative complex, and then show that this mutant RXFP1 is deficient in its sub-picomolar responses to relaxin. For example, if a mutant RXFP1 could be created that did not associate with AKAP-79 (presumably a mutation somewhere between amino acids 673 and 703, the region of RXFP1 that binds to AKAP-79 as shown in Figure 6C ), then this mutant could be used to address the point raised above in point #2 (whether or not AKAP-79 is truly required for linking RXFP1 to AC2) and could also be used in functional studies to establish the importance of the putative cellular complex for RXFP1 signaling.
We have now completed much more extensive co-IP studies (as described in the point above) and have furthermore assessed the effect of knockdown of either AKAP79 or β-arrestin 2. This has revealed that the activation (AKAP79 and AC2) and regulatory (β-arrestin 2, PDE4D3 and PKA) components of the signalosome are quite independent, and indeed are located within spatially distinct regions of the RXFP1 C-terminal tail. Thus knockdown of AKAP79 prevented the co-IP between AC2 and all proteins within the complex (in AC2 co-IP studies), whereas knockdown of AKAP79 only affected the co-IP between PDE4D3 and AC2 (and not between PDE4D3 and β-arrestin 2, PKA or RXFP1 in PDE4D3 co-IP studies). Similarly, knockdown of β-arrestin
We Thank you very much for having submitted an improved version of the original paper (EMBOJ-2010-73711R-A) paper for consideration to The EMBO Journal. As mentioned in my initial decision, some of the original as well as so far unbiased scientists were kind enough to judge insight in quality provided by this new version of your study. Although overall supportive, one of the original referees still demands addressing a major point raised during initial review; namely to compare complex formation in the absence or presence of agonist. Together with this essential experiment, I would also like to offer you a chance to respond to the additional remarks made by this referee that should overall further strengthen your case. Please take the necessary time to appropriate respond to this before submitting an ultimate version for final assessment! Yours sincerely,
Editor
REFEREE REPORTS
This revised manuscript describes experiments that make use of cAMP biosensors in HEK293 cells to assess the ability of relaxin to increase cAMP levels through the RXFP1 receptor. The authors define a previously-undescribed sub-picomolar response of RXFP1 that can be selectively disrupted by blocking AKAP interactions, knocking down beta-arrestin2, or inhibiting the activity of PDE4 or PKA. The authors also present data to support the idea that RXFP1 can be found in complex with AKAP-79, beta-arrestin2, PDE4D3 and AC2. As noted in the original reviews of this manuscript, the functional and pharmacological data shown here are fairly novel and interesting. In this revision, the authors have added in a significant amount of new protein-protein interaction data to support their model. However, there are inconsistencies in the data that make the conclusions not fully convincing. Specific comments are as follows:
1. Some of the co-IP data from Figure 7 do not match the authors' conclusions. For example, in the IP of PDE4D3 (Fig. 7A, right) , co-IP of AC2 is clearly evident even in the absence of RXFP1. Cotransfection of RXFP1 somewhat enhances, but is not required for, the AC2/PDE4D3 interaction. Yet, in the authors' model, the AC2/PDE4D3 interaction is dependent on the presence of RXFP1, which is a conclusion that does not match the data. Similarly, in the IP of AC2-HA (Fig. 7A, left) , co-IP of PKA is clearly evident even in the absence of RXFP1. Again, these data do not match the authors' conclusion that PKA can only interact with AC2 through RXFP1.
2. The authors' model that beta-arrestin2 forms a stable complex with RXFP1 is inconsistent with previous studies, notably Callander et al. (2009) , who could not detect any significant interaction at all between RXFP1 and beta-arrestins. What explains this difference?
3. If RXFP1 and beta-arrestin2 form a stable, preassembled complex, as the author's propose, then this complex should be completely inactive with regard to G protein signaling. There are many hundreds of papers revealing that GPCR interactions with beta-arrestins versus G proteins are mutually exclusive. Nonetheless, the authors' model is that beta-arrestin2 forms a preassembled complex with RXFP1, and this complex couples to G proteins to mediate signaling by RXFP1 in response to low doses of agonist. The only way that this could make sense is if RXFP1 releases beta-arrestin2 upon agonist stimulation so that it can couple to G proteins. Thus, the co-IP experiments from Figure 7 should be repeated in the absence and presence of agonist stimulation (as was suggested in the original review of this manuscript), to see if it is indeed true that agonist stimulation allows the displacement of preassembled beta-arrestin2 by G proteins to mediate RXFP1 signaling. Alternatively, the authors need to provide more compelling evidence that RXFP1 is unlike other GPCRs in that it can simultaneously associate with G proteins and beta-arrestins.
4. In the authors' model, PKA is recruited to RXFP1 by beta-arrestin2. However, beta-arrestins are not known to interact with PKA. In fact, a detailed proteomic analysis of all proteins that associate either directly or indirectly with beta-arrestins (Xiao et al., PNAS 104:12011, 2007) failed to reveal evidence of any PKA isoforms in beta-arrestin complexes. The observation of a direct association between PKA and beta-arrestins, if true, would be an extremely important discovery. Thus, given the importance of this issue, the authors need to do much more to prove the PKA/beta-arrestin association. If PKA is indeed part of the complexes that the authors are studying, it would seem to make a lot more sense for PKA to associate with the complexes via AKAP79, a protein that was first discovered based on its ability to bind to PKA, as opposed to beta-arrestins, which have never been shown to associate (either directly or indirectly) with PKA.
The authors have done an excellent job in addressing the significant comments that I made. I think that this is a very exciting, topical and substantial work that provides a novel paradigm in terms of GPCR signaling complexes.
This revised manuscript offers insights into a new paradigm for cell signaling in which supermolecular assemblies of G-protein-based signaling devices occur in advance of the trigger event. Although the initial concerns have merit, some of the earlier comments seem to overly interpret what I find to be well-founded novel conclusions. To this referee, a paradigm for preassembled devices based on novel data seems important to announce to the cell signaling community. This revised manuscript describes experiments that make use of cAMP biosensors in HEK293 cells to assess the ability of relaxin to increase cAMP levels through the RXFP1 receptor. The authors define a previously-undescribed sub-picomolar response of RXFP1 that can be selectively disrupted by blocking AKAP interactions, knocking down beta-arrestin2, or inhibiting the activity of PDE4 or PKA. The authors also present data to support the idea that RXFP1 can be found in complex with AKAP-79, beta-arrestin2, PDE4D3 and AC2. As noted in the original reviews of this manuscript, the functional and pharmacological data shown here are fairly novel and interesting. In this revision, the authors have added in a significant amount of new protein-protein interaction data to support their model. However, there are inconsistencies in the data that make the conclusions not fully convincing. Specific comments are as follows:
1. Some of the co-IP data from Figure 7 do not match the authors' conclusions. For example, in the IP of PDE4D3 (Fig. 7A, right) , co-IP of AC2 is clearly evident even in the absence of RXFP1. Cotransfection of RXFP1 somewhat enhances, but is not required for, the AC2/PDE4D3 interaction. Yet, in the authors' model, the AC2/PDE4D3 interaction is dependent on the presence of RXFP1, which is a conclusion that does not match the data. Similarly, in the IP of AC2-HA (Fig. 7A, left) , co-IP of PKA is clearly evident even in the absence of RXFP1. Again, these data do not match the authors' conclusion that PKA can only interact with AC2 through RXFP1. and PDE4D3, AC2 and PKA, and AC2 and AKAP79. This observation is completely to be expected based on recent studies showing that AKAP79 can interact with AC2 (Efendiev et al., 2010) , and by its nature AKAP79 can also scaffold PKA (Stefan et al., 2007) , AKAP9/yotiao (Terrenoire et al., 2009 ), AKAP250/gravin (McCahill et al 2005 Willoughby et al., 2006) , AKAP450 (Taskén et al., 2001; McCahill et al., 2005) and mAKAP (Dodge et al., 2001) McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G & Houslay MD (2005) . Interestingly, this receptor, like RXFP1, does not show significant receptor desensitization and internalization following stimulation with dopamine . Furthermore, the receptor co-immunoprecipitates with β-arrestin 2 constitutively, and this does not change following receptor stimulation . Strikingly, GFP-tagged β-arrestin 2 showed cytosolic localization in cells expressing the D4 receptor, despite restricted localization of the D4 receptor to the plasma membrane, and this localization did not change following receptor stimulation . 3. If RXFP1 and beta-arrestin2 form a stable, preassembled complex, as the author's propose, then this complex should be completely inactive with regard to G protein signaling. There are many hundreds of papers revealing that GPCR interactions with beta-arrestins versus G proteins are mutually exclusive. Nonetheless, the authors' model is that beta-arrestin2 forms a preassembled complex with RXFP1, and this complex couples to G proteins to mediate signaling by RXFP1 in response to low doses of agonist. The only way that this could make sense is if RXFP1 releases beta-arrestin2 upon agonist stimulation so that it can couple to G proteins. Thus, the co-IP experiments from Figure 7 should be repeated in the absence and presence of agonist stimulation (as was suggested in the original review of this manuscript), to see if it is indeed true that agonist stimulation allows the displacement of preassembled beta-arrestin2 by G proteins to mediate RXFP1 signaling. Alternatively, the authors need to provide more compelling evidence that RXFP1 is unlike other GPCRs in that it can simultaneously associate with G proteins and beta-arrestins.
In our co-immunoprecipitation experiments, we did see a basal level of association between AC2
We , despite coupling to Gα q/11 , Gα 12/13 and Gα i/o (Bikle et al., 2007 (Shenoy et al., 2006 (Shenoy et al., 2006) . The authors suggest that the β-arrestin 2 recruited to a GRK2 phosphorylated receptor may not be conformationally competent for engaging efficient ERK1/2 activation (Shenoy et al., 2006) Fig 4) , and the text of the manuscript has been altered on pg. 15-16. 4. In the authors' model, PKA is recruited to RXFP1 by beta-arrestin2. However, beta-arrestins are not known to interact with PKA. In fact, a detailed proteomic analysis of all proteins that associate either directly or indirectly with beta-arrestins (Xiao et al., PNAS 104:12011, 2007) failed to reveal evidence of any PKA isoforms in beta-arrestin complexes. The observation of a direct association between PKA and beta-arrestins, if true, would be an extremely important discovery. Thus, given the importance of this issue, the authors need to do much more to prove the PKA/beta-arrestin association. If PKA is indeed part of the complexes that the authors are studying, it would seem to make a lot more sense for PKA to associate with the complexes via AKAP79, a protein that was first discovered based on its ability to bind to PKA, as opposed to beta-arrestins, which have never been shown to associate (either directly or indirectly) with PKA.
Indeed the extensive proteomics study by Xiao et al. (2007) Figure 3G & H) ; disruption of PKA/AKAP interactions using the peptide inhibitor St-Ht31 abolished the 10 fM relaxin response, whereas inhibition of PKA (or PDE4D and β-arrestin 2; Figure 4) enhanced the basal cAMP level, revealing the constitutive activity of the RXFP1-signalosome. Thus both functionally and biochemically, the PKAα-catalytic subunit appears to be associated with β-arrestin 2 rather than AKAP79.
It is expected that the regulatory subunit of PKA (PKA-RII) associates with AKAP79 (as shown previously, ; however, the experiments described above strongly support an association between the catalytic subunit of PKA and β-arrestin 2. As such, it may be that the regulatory PKA subunits are associating with AKAP79 as originally demonstrated Xiao et al. (2007) within the
